Novo CEO pressed by Senate to chop costs of obesity, diabetic issues drugs CEO Lars Fruergaard Jørgensen told lawmakers the corporation would think about new talks with insurers with regard to the listing price ranges of Wegovy and copyright if they pledge to maintain the medicines on their own formularies. https://edgaryoevk.bloginwi.com/64396514/about-healthcare-news